AN-1

AN-1 is a synthetic derivative of progesterone currently being investigated for its neuroprotective potential in the treatment of Alzheimer's disease. It functions as a dual inhibitor of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are responsible for the breakdown of the neurotransmitter acetylcholine in the brain. By inhibiting these enzymes, AN-1 aims to restore cholinergic signaling, which is typically impaired in patients with Alzheimer's. Additionally, AN-1 exhibits significant antioxidant activity, specifically in scavenging DPPH free radicals, which may help protect neurons from oxidative stress-induced damage. In preclinical studies using scopolamine-induced amnesic animal models, AN-1 has demonstrated the ability to ameliorate cognitive deficits, improving both working memory and locomotor activity.